A detailed history of Handelsbanken Fonder Ab transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 43,011 shares of IONS stock, worth $1.57 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
43,011
Previous 33,911 26.83%
Holding current value
$1.57 Million
Previous $1.62 Million 6.62%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 04, 2024

BUY
$40.06 - $51.86 $364,546 - $471,926
9,100 Added 26.83%
43,011 $1.72 Million
Q1 2024

May 13, 2024

BUY
$42.03 - $53.55 $290,007 - $369,495
6,900 Added 25.55%
33,911 $1.47 Million
Q4 2023

Feb 01, 2024

BUY
$43.39 - $51.63 $138,848 - $165,216
3,200 Added 13.44%
27,011 $1.37 Million
Q3 2023

Oct 19, 2023

SELL
$38.5 - $47.13 $265,650 - $325,197
-6,900 Reduced 22.47%
23,811 $1.08 Million
Q2 2023

Aug 02, 2023

BUY
$34.73 - $43.33 $423,705 - $528,626
12,200 Added 65.91%
30,711 $1.26 Million
Q2 2022

Aug 03, 2022

BUY
$31.71 - $43.0 $152,208 - $206,400
4,800 Added 35.01%
18,511 $685,000
Q1 2022

May 11, 2022

SELL
$29.88 - $37.04 $319,716 - $396,328
-10,700 Reduced 43.83%
13,711 $508,000
Q2 2021

Aug 03, 2021

BUY
$34.54 - $47.25 $48,356 - $66,150
1,400 Added 6.08%
24,411 $974,000
Q1 2021

Apr 29, 2021

SELL
$42.51 - $63.78 $153,036 - $229,608
-3,600 Reduced 13.53%
23,011 $1.04 Million
Q4 2020

Feb 11, 2021

BUY
$45.3 - $60.27 $194,790 - $259,161
4,300 Added 19.27%
26,611 $1.51 Million
Q2 2020

Aug 13, 2020

BUY
$46.85 - $61.05 $1.05 Million - $1.36 Million
22,311 New
22,311 $1.32 Million

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.19B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Handelsbanken Fonder Ab Portfolio

Follow Handelsbanken Fonder Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.